ATE510819T1 - Neue rar rezeptor aktivierende liganden und deren verwendung in der humanmedizin und der kosmetik - Google Patents

Neue rar rezeptor aktivierende liganden und deren verwendung in der humanmedizin und der kosmetik

Info

Publication number
ATE510819T1
ATE510819T1 AT04791557T AT04791557T ATE510819T1 AT E510819 T1 ATE510819 T1 AT E510819T1 AT 04791557 T AT04791557 T AT 04791557T AT 04791557 T AT04791557 T AT 04791557T AT E510819 T1 ATE510819 T1 AT E510819T1
Authority
AT
Austria
Prior art keywords
cosmetics
human medicine
rar receptor
new rar
ligands
Prior art date
Application number
AT04791557T
Other languages
English (en)
Inventor
Thibaud Biadatti
Anne-Pascale Luzy
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Application granted granted Critical
Publication of ATE510819T1 publication Critical patent/ATE510819T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
AT04791557T 2003-10-17 2004-10-15 Neue rar rezeptor aktivierende liganden und deren verwendung in der humanmedizin und der kosmetik ATE510819T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312154A FR2861069B1 (fr) 2003-10-17 2003-10-17 NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS RARs, UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE
PCT/FR2004/002646 WO2005037772A2 (fr) 2003-10-17 2004-10-15 NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS RARs, UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE

Publications (1)

Publication Number Publication Date
ATE510819T1 true ATE510819T1 (de) 2011-06-15

Family

ID=34385243

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04791557T ATE510819T1 (de) 2003-10-17 2004-10-15 Neue rar rezeptor aktivierende liganden und deren verwendung in der humanmedizin und der kosmetik

Country Status (8)

Country Link
US (1) US7439396B2 (de)
EP (1) EP1680395B1 (de)
AR (1) AR046111A1 (de)
AT (1) ATE510819T1 (de)
CA (1) CA2539059C (de)
ES (1) ES2366627T3 (de)
FR (1) FR2861069B1 (de)
WO (1) WO2005037772A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2931661B1 (fr) 2008-05-30 2010-07-30 Galderma Res & Dev Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise et un retinoide.
AU2011242956B2 (en) 2010-04-19 2015-01-22 Cirius Therapeutics, Inc. Novel synthesis for thiazolidinedione compounds
NZ606574A (en) 2010-08-10 2015-02-27 Metabolic Solutions Dev Co Llc Novel synthesis for thiazolidinedione compounds
NZ606597A (en) * 2010-08-10 2014-12-24 Metabolic Solutions Dev Co Llc Synthesis for thiazolidinedione compounds
US10702604B2 (en) 2012-06-01 2020-07-07 Galderma Research & Development Lipid nanocapsules comprising a retinoid, nanodispersion and composition containing the same, process for preparing the same and use thereof in dermatology
FR2991174B1 (fr) 2012-06-01 2014-12-26 Galderma Res & Dev Composition dermatologique comprenant des oleosomes et des retinoides, son procede de preparation et son utilisation
FR2991171B1 (fr) 2012-06-01 2014-05-23 Galderma Res & Dev Procede de preparation d'une composition dermatologique comprenant des oleosomes
FR2991172A1 (fr) 2012-06-01 2013-12-06 Galderma Res & Dev Compositions pharmaceutiques topiques comprenant des microcapsules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
WO1994015901A1 (en) * 1993-01-11 1994-07-21 Ligand Pharmaceuticals Inc. Compounds having selectivity for retinoid x receptors
FR2750426B1 (fr) * 1996-06-28 1998-08-07 Cird Galderma Nouveaux composes biaryles heterocycliques et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetique
JP2001039828A (ja) * 1999-07-08 2001-02-13 Haarmann & Reimer Gmbh ベンズアルドキシムを含んでなる局所用化粧品組成物
DE19960105A1 (de) * 1999-12-14 2001-06-21 Haarmann & Reimer Gmbh Catecholoxime und ihre Verwendung in kosmetischen und dermatologischen Zubereitungen

Also Published As

Publication number Publication date
WO2005037772A3 (fr) 2005-09-01
FR2861069B1 (fr) 2005-12-09
EP1680395A2 (de) 2006-07-19
US20070004726A1 (en) 2007-01-04
CA2539059A1 (fr) 2005-04-28
EP1680395B1 (de) 2011-05-25
ES2366627T3 (es) 2011-10-24
WO2005037772A2 (fr) 2005-04-28
FR2861069A1 (fr) 2005-04-22
US7439396B2 (en) 2008-10-21
AR046111A1 (es) 2005-11-23
CA2539059C (fr) 2013-02-12

Similar Documents

Publication Publication Date Title
ATE542791T1 (de) Neue liganden als rar-rezeptormodulatoren und deren verwendung in der humanmedizin und kosmetik
PL379553A1 (pl) Ligandy receptora waniloidowego oraz ich zastosowanie w leczeniu
DE602004010785D1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
ATE420084T1 (de) Neue imidazolderivate und deren verwendung als pharmazeutische mittel
IL166396A0 (en) Vanilloid receptor ligands and their use in treatments
ATE378391T1 (de) Seifenstück mit gleichzeitigen hautabschilfernden und feuchtigkeitsspendenden eigenschaften
IL173013A0 (en) New branched sulfates for use in personal care formulations
ATE431830T1 (de) Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
ATE469631T1 (de) Verbesserungen in pulverpressung und beschichtung
ATE430145T1 (de) 3-ä(2-ä 4-(hexyloxycarbonylamino-imino-methyl)- phenylaminoü-methylü-1-methyl-1h-benzimidazol-5 carbonyl)-pyridin-2-yl-aminoü -propionsäure- ethylester -methansulfonat und dessen verwendung als arzneimittel
DK1620118T3 (da) Reversible pegylerede lægemidler
IL172316A0 (en) Novel compounds and their use in therapy
AU2003278807A8 (en) KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
AP2006003820A0 (en) Piperazin derivatives and their use in controllingpests
EP1572724A4 (de) Kdr und vegf/kdr bindungspeptide und ihre verwendung bei der diagnose und therapie
DE602004024338D1 (de) Pflanzenextrakt und seine pharmazeutische und kosmetische verwendung
DE69919414D1 (de) Inverser latex und verwendung in der kosmetik
ATE510819T1 (de) Neue rar rezeptor aktivierende liganden und deren verwendung in der humanmedizin und der kosmetik
PL372556A1 (en) Novel ligands that are inhibitors of the rar receptors, process for preparing them and use thereof in human medicine and in cosmetics
DE602004022169D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
SG123742A1 (en) Device for health and beauty care
FR2838960B1 (fr) Composition comprenant des photochromes et son utilisation en cosmetique
ATE432254T1 (de) Neue liganden, bei denen es sich um aktivatoren des rar-rezeptors handelt, verwendung in der humanmedizin und in kosmetika
DK1660532T3 (da) Fusionspolypeptider, og anvendelse deraf i antivaskulær tumorterapi
ATE456573T1 (de) Nmb0928-protein und dessen verwendung in pharmazeutischen formulierungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties